Phase II Study of Enzastaurin, a Protein Kinase C Beta Inhibitor, in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma - Concepedia

Concepedia

Publication | Closed Access

Phase II Study of Enzastaurin, a Protein Kinase C Beta Inhibitor, in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

230

Citations

21

References

2007

Year

Michael J. Robertson, Brad S. Kahl, Julie M. Vose, Sven de Vos, Mary Laughlin, Patrick J. Flynn, Kendrith M. Rowland, José C. Cruz, Stuart L. Goldberg, Luna Musib,

Journal of Clinical Oncology

Abstract

Treatment with enzastaurin was well-tolerated and associated with prolonged FFP in a small subset of patients with relapsed or refractory DLBCL. Further studies of enzastaurin in DLBCL are warranted.

References

	Year	Citations

Page 1